{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.8","upperLimit":"96.1","value":"75"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"PFS will be defined as time from the initiation of protocol treatment to the I of any of the following events: disease progression or disease recurrence or death from any cause. Patients with local calls of disease progression (i.e. calls made by the treating institution), will be counted as having had an event, even if the central review does not declare progression. PFS along with the confidence intervals will be estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive vemurafenib PO BID on day 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Vemurafenib)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From the initiation of protocol treatment to the occurrence of any of the following events: disease progression or disease recurrence or death from any cause, assessed up to 5 years","title":"Progress Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}